| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 82,031 | 41,739 | ||
| Short-term investments | 20,161 | 72,416 | ||
| R&d benefit receivable | 22,152 | 19,957 | ||
| Other current assets | 9,260 | 14,356 | ||
| Trade receivables | 28 | 85 | ||
| Total current assets | 133,632 | 148,553 | ||
| Property, plant and equipment | 1,655 | 1,775 | ||
| Operating lease right-of-use asset | 192 | 58 | ||
| Goodwill | 10,612 | 10,617 | ||
| Other intangible assets | 300 | 317 | ||
| Other long-term assets | 399 | 3,913 | ||
| Total assets | 146,790 | 165,233 | ||
| Contract liabilities | 301 | 457 | ||
| Trade and other payables | 16,993 | 14,311 | ||
| Operating lease liabilities, current | 85 | 0 | ||
| Total current liabilities | 17,379 | 14,768 | ||
| Contract liabilities | 55,251 | 56,310 | ||
| Operating lease liabilities | 97 | - | ||
| Total liabilities | 72,727 | 71,078 | ||
| Ordinary shares - par value 0.05 per share 141,701,848 shares issued at september 30, 2025 (december 31, 2024 141,674,074) | 10,290 | 10,290 | ||
| Additional paid-in capital | 617,648 | 615,113 | ||
| Accumulated deficit | -550,802 | -529,844 | ||
| Accumulated other comprehensive loss | -3,073 | -1,404 | ||
| Total shareholders' equity | 74,063 | 94,155 | ||
| Total liabilities and shareholders' equity | 146,790 | 165,233 | ||
Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN)